Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Standards of Care II01:19

Standards of Care II

Nurses bear specific legal responsibilities under several federal statutes, including:
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial.

JAMA oncology·2026
Same author

The Landscape of Prostate Tumour Methylation.

Cancer discovery·2026
Same author

A Multidisciplinary Approach to Prevention and Treatment of Late Genitourinary Adverse Events After Radiotherapy for Prostate Cancer.

European urology·2026
Same author

Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis.

JAMA oncology·2026
Same author

Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients.

European urology oncology·2026
Same author

Cost-effectiveness of an artificial intelligence predictive model for guiding androgen deprivation therapy in intermediate-risk prostate cancer.

JNCI cancer spectrum·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

The Evolving Clinical Utility of Gene Expression Profiling in Cutaneous Melanoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Daniel E Spratt1, Sandy Srinivas2, Nabil Adra3

  • 11Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 14, 2026
PubMed
Summary
This summary is machine-generated.

The National Comprehensive Cancer Network (NCCN) updated its prostate cancer guidelines in 2026. Key changes include removing the very-low-risk group and refining active surveillance principles for nonmetastatic disease.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: May 16, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

  • Oncology
  • Urology
  • Clinical Guidelines

Background:

  • The NCCN Guidelines for Prostate Cancer provide comprehensive recommendations for diagnosis, staging, risk assessment, and treatment of prostate cancer.
  • These guidelines cover localized, regional, recurrent, and metastatic disease stages.
  • Regular updates ensure the guidelines reflect the latest scientific evidence and clinical consensus.

Purpose of the Study:

  • To summarize key updates from the 2026 NCCN Guidelines for Prostate Cancer.
  • To highlight changes specifically related to nonmetastatic prostate cancer management.
  • To inform clinicians about revisions in risk stratification, active surveillance, and focal therapy recommendations.

Main Methods:

  • Review of NCCN Guidelines Insights detailing panel discussions on 2026 updates.
  • Focus on changes pertaining to nonmetastatic prostate cancer.
  • Analysis of specific revisions concerning risk groups, active surveillance, and focal therapy.

Main Results:

  • The very-low-risk group for prostate cancer has been eliminated from the guidelines.
  • Updates have been made to the Principles of Active Surveillance.
  • The guidelines now emphasize caution regarding the use of focal therapy in newly diagnosed patients.

Conclusions:

  • The 2026 NCCN Guidelines for Prostate Cancer reflect significant adjustments in managing nonmetastatic disease.
  • These updates aim to optimize patient care by refining risk assessment and treatment strategies.
  • Clinicians should be aware of these changes for accurate prostate cancer management.